Synergy Pharmaceuticals — Investor Presentation (October 2014)
33 slides from Synergy Pharmaceuticals's investor presentation, Oct 2, 2014
Slide 1: Synergy Pharmaceuticals Corporate Presentation
@ Synergy Pharmaceuticals Corporate Presentation
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “wi
Slide 3: Our Team: GI Expertise & Proven Track Record of Execution
3 Our Team: GI Expertise & Proven Track Record of Execution Gary Jacob, Ph.D. Chairman & CEO Over 25 years of experience in pharma and biotech across multiple disciplines, including: R & D, operations and business development Kunwar Shailubhai, PhD Chief Scientific Officer Major discoverer of Plecan
Slide 4: Our Focus: Pioneering GI Research & Development
4 Our Focus: Pioneering GI Research & Development NATURAL PHYSIOLOGY MEETS BREAKTHROUGH SCIENCE Advanced clinical programs with multiple value drivers Unique mechanism-of-action based on a naturally occurring human GI hormone Exclusive worldwide rights Strong patent portfolio Experienced management
Slide 5: Our Platform: Discovered & Developed by Synergy
5 Our Platform: Discovered & Developed by Synergy COMPOUND INDICATION PHASE 1 PHASE 2 PHASE 3 PLECANATIDE Chronic Idiopathic Constipation (CIC) Irritable Bowel Syndrome with Constipation (IBS-C) SP-333 Opioid-Induced Constipation (OIC) Ulcerative Colitis (UC)
Slide 6: Our Approach: Based on a Natural Human GI Hormone - Uroguanylin
6 Our Approach: Based on a Natural Human GI Hormone - Uroguanylin UROGUANYLIN (Natural GI Hormone) PLECANATIDE CIC/IBS-C SP-333 OIC/UC
Slide 7: Physiological Mechanism of Action
7 Physiological Mechanism of Action 1 2 3 Plecanatide SP-333 Uroguanylin (UroG) activates GC-C receptors in the gut GC-C receptor stimulates cyclic GMP synthesis C-GMP activates CFTR, moving fluid into the intestine for normal digestion Plecanatide/SP-333 activate GC-C, restoring normal GI function
Slide 8: Plecanatide: Novel Analog of Natural Uroguanylin
8 Plecanatide: Novel Analog of Natural Uroguanylin NDDCELCVNVACTGCL NDECELCVNVACTGCL KEY AMINO ACID SUBSTITUTION (1) D. Liu, et. al., Anticancer Research, 29: 3777-3784 (2009) Uroguanylin Plecanatide Binding constant to GC-C receptors is 8-fold higher than uroguanylin(1) Pharmacological activity mim
Slide 9: Natural GC-C Agonist vs. Bacterial Enterotoxin
9 Natural GC-C Agonist vs. Bacterial Enterotoxin Linaclotide: Enterotoxin Analog NDDCELCVNVACTGCL NDECELCVNVACTGCL NSSNYCCELCCNPACTGCY CCEYCCNPACTGCY ST Peptide: Produced by E. coli Bacteria Uroguanylin: Natural GC-C Agonist Plecanatide: Uroguanylin Analog Linaclotide is a truncated version of a bac
Slide 10: CIC/IBS-C Market Overview
@® Synergy Pharmaceuticals CIC/IBS-C Market Overview
Slide 11: Growing US Market Opportunity
11 Growing US Market Opportunity Millions of US adults with CIC/IBS-C Around 35 million US adults with CIC Estimated 13 million US adults with IBS-C CIC population expected to grow CIC affects around 50% of the US elderly – 74% nursing home residents 65+ population expected to reach 80 million by 20
Slide 12: US Constipation Rx Market Volume Accelerating
12 US Constipation Rx Market Volume Accelerating US Constipation* Rx Annual Volume 6 5 4 3 0 2 1 2013 +11% CAGR 2011 2012 2010 Linzess Amitiza Others** Since launch, Linzess has grown the market as opposed to capturing volume from alternative therapies From Q1 2013 to Q1 2014, total market volume ha
Slide 13: US Constipation Rx Market Value Growing
13 US Constipation Rx Market Value ($) Growing US Constipation* Rx Annual Sales 600 500 550 0 100 150 200 50 450 300 400 350 250 +21% CAGR 2013 2010 2012 2011 Others** Amitiza Linzess Both Linzess and Amitiza have driven sales growth in the market From Q1 2013 to Q1 2014, the market has grown by 55%
Slide 14: Plecanatide CIC Clinical Program
Plecanatide CIC Clinical Program
Slide 15: Plecanatide Phase 2b/3 CIC Trial: Study Overview
15 Plecanatide Phase 2b/3 CIC Trial: Study Overview Aim: Assess the safety and efficacy of 0.3, 1.0 and 3.0 mg plecanatide doses vs. placebo in CIC patients Patient Population: 951 patients with CIC (Modified Rome III Criteria) Primary Endpoint: Proportion of Durable Overall Responders (fulfills ≥ 3
Slide 16: Plecanatide Phase 2b/3 CIC Trial: Results Summary
16 Placebo n=236 3.0 mg n=237 p value % CSBM Responders 10.7 19 p= <0.01 CSBM Frequency 1.03 2.13 p= <0.001 SBM Frequency 1.30 2.88 p= <0.001 Stool Consistency 0.81 2.01 p= <0.001 Mean Straining Change -1.24 -2.07 p= <0.001 Plecanatide Phase 2b/3 CIC Trial: Results Summary Plecanatide 3.0 mg dose sh
Slide 17: Plecanatide Phase 2b/3 CIC Trial: Results Summary
17 Plecanatide Phase 2b/3 CIC Trial: Results Summary % Responders * = p<0.05; ** = p < 0.01; *** = p < 0.001 Treatment Week Treatment week Bristol Stool Form Scale Score Stool Consistency (BSFS) Weekly Responder Rates Plecanatide 3.0 mg demonstrated immediate and sustained effect
Slide 18: Plecanatide Phase 2b/3 CIC Trial: Clear Dose-Response for Efficacy
18 Plecanatide Phase 2b/3 CIC Trial: Clear Dose-Response for Efficacy * = p<0.05; ** = p < 0.01; *** = p < 0.001 *** *** ***
Slide 19: Plecanatide Phase 2b/3 CIC Trial: Diarrhea Plateau Effect
19 Plecanatide Phase 2b/3 CIC Trial: Diarrhea Plateau Effect All AE Diarrhea 9.7% 8.4% 5.5% 1.3% Diarrhea incidence did not increase proportionately with dose and appears to reach a plateau at the high end of the dose range
Slide 20: Plecanatide Phase 2b/3 CIC Trial: Safety Summary
20 Placebo n=236 3.0 mg n=237 Serious Adverse Events (AE) 5 (2.1%) 2 (0.8%) Treatment-emergent (TE) AEs 96 (40.7%) 106 (44.7%) AEs leading to withdrawal 8 (3.4%) 13 (5.5%) All Diarrhea TEAEs 3 (1.3%) 23 (9.7%) Severe Diarrhea TEAEs 0 1 (0.4%) Withdrawal due to Diarrhea 1 (0.4%) 7 (3.0%) Plecanatide
Slide 21: Plecanatide Pivotal Phase 3 CIC Trials: Program Overview
21 Plecanatide Pivotal Phase 3 CIC Trials: Program Overview Aim: Two, randomized, 12-week, double-blind, placebo-controlled trials to confirm the safety and efficacy of plecanatide in CIC patients Treatment Groups: 3.0 and 6.0 mg oral tablet plecanatide or placebo once-daily Estimated Enrollment: 13
Slide 22: Plecanatide IBS-C Clinical Program
Plecanatide IBS-C Clinical Program
Slide 23: Plecanatide Phase 2b IBS-C Trial: Study Overview
23 Plecanatide Phase 2b IBS-C Trial: Study Overview Screening up to 6 weeks Baseline 2 weeks Treatment 12 weeks Post-Tx 2 weeks Patients called in daily to IVRS Study Aim: Assess the efficacy and safety of 0.3, 1.0, 3.0 and 9.0 mg plecanatide doses vs. placebo in IBS-C patients Population: 424 patie
Slide 24: Plecanatide Phase 2b IBS-C Trial: Preliminary Top-line Data
24 Plecanatide Phase 2b IBS-C Trial: Preliminary Top-line Data 1.0, 3.0 and 9.0 mg dose groups demonstrated statistical significance for the study’s primary endpoint (CSBM frequency) Safe and well tolerated at all doses with no treatment-related serious adverse events 3.0 mg dose consistently demons
Slide 25: Plecanatide Phase 2b IBS-C Trial: Overall Responder Endpoint
25 41.9% * 24.7% *p< 0.05 n = 85 n = 86 Plecanatide Phase 2b IBS-C Trial: Overall Responder Endpoint (FDA Approval Endpoint) Overall Responder = fulfills both ≥ 30% reduction in worst abdominal pain and Increase of ≥ 1 CSBMs from baseline in the same week for at least 50% of the weeks (6/12 wks)
Slide 26: Plecanatide Phase 2b IBS-C Trial: Preliminary Top-line Data
26 Placebo n=85 3.0 mg n=86 p value CSBM frequency/ 12 weeks 1.29 2.74 p= <0.001 Worst Abdominal Pain Intensity -1.4 (-24.5%) -2.0 (-33.9%) p= <0.05 Stool Consistency 1.01 2.49 p= <0.001 Diarrhea Rate 0 9.3% Plecanatide Phase 2b IBS-C Trial: Preliminary Top-line Data Plecanatide 3.0 mg demonstrated
Slide 27: Plecanatide Phase 2b IBS-C Trial: End-of-Phase FDA Meeting Highlights
27 Plecanatide Phase 2b IBS-C Trial: End-of-Phase 2 FDA Meeting Highlights Agreement reached with FDA on pivotal phase 3 IBS-C studies regarding trial duration, study population, number of trials and primary endpoint Plecanatide 3.0 mg and 6.0 mg doses selected (consistent with CIC registration tria
Slide 28: Plecanatide Phase 3 IBS-C Trials: Program Overview
28 Plecanatide Phase 3 IBS-C Trials: Program Overview Aim: Two, randomized, 12-week, double-blind, placebo-controlled studies to confirm the safety and efficacy of plecanatide in IBS-C patients Treatment Groups: 3.0 and 6.0 mg oral tablet plecanatide or placebo once-daily Estimated Enrollment: 1,050
Slide 29: SP-333 Clinical Program
(6?) Synergy Pharmaceuticals SP-333 Clinical Program
Slide 30: SP-333: Superior Stability Expands the Potential
30 SP-333: Superior Stability Expands the Potential dNDECELCVNVACTGCdL NDDCELCVNVACTGCL Next-Generation Uroguanylin Analog Resistant to proteolysis in simulated intestinal fluid Highly potent and stable peptide Pharmacologic activity mimics natural physiology Essentially non-systemic Once-daily oral
Slide 31: SP-333 Phase 2 OIC Trial: Study Overview
31 SP-333 Phase 2 OIC Trial: Study Overview Aim: Assess the safety and efficacy of SP-333 in OIC patients receiving chronic opioid therapy for ≥ 3 months Treatment Groups: 1.0, 3.0 and 6.0 mg SP-333 vs. placebo once-daily Estimated Enrollment: 260 OIC patients Treatment Duration: 4 weeks Primary End
Slide 32: Corporate Summary
@® Synergy Pharmaceuticals Corporate Summary
Slide 33: Anticipated Milestones
33 Anticipated Milestones 2013 Plecanatide SP-333 CIC IBS-C OIC UC EOP2 Meeting Phase 2b/3 Positive Top-line Data 2014 2015 2016 CIC Phase 3 Pivotal Program US NDA Filing Phase 2b Trial – Positive Top-line Data US NDA Filing Phase 2 Trial Top-line Data Phase 2 Trial Completed SAD/MAD Phase 1 Trials
Synergy Pharmaceuticals — Investor Presentation (October 2014) on 6ix